Transaction Expands PetIQ's Portfolio of Brands and Strengthens its Position as a Leading Pet Health & Wellness Platform with Additional Science-Backed Products

此次交易丰富了PetIQ的品牌组合，并通过增加更多经科学验证的产品，巩固其作为领先宠物健康与福祉平台的地位。

EAGLE, Idaho

爱达荷州伊格尔

,

，

July 29, 2026

2026年7月29日

/PRNewswire/ -- PetIQ, Inc. ('PetIQ'), a leading pet health and wellness company and portfolio company of Bansk Group, today announced it has closed the acquisition of MYOS Corp ('MYOS') and its Fortetropin®-based product portfolio of muscle health products for the animal health category, spanning both consumer-facing supplements and veterinary exclusive formulations.

/美通社/ -- 宠物健康与保健领域领先企业、Bansk Group旗下投资组合公司PetIQ, Inc.（“PetIQ”）今日宣布，已完成对MYOS Corp（“MYOS”）及其基于Fortetropin®的肌肉健康产品组合的收购，该产品组合涵盖面向消费者的补充剂及兽医专有配方，适用于动物健康类别。

Terms of the transaction were not disclosed. .

交易条款未予披露。

The acquisition adds a leading, clinically-studied muscle health brand and its patented Fortetropin® ingredient technology to PetIQ's growing portfolio of pet medications, supplements, and wellness brands, further strengthening its position as a category leader in Pet Health & Wellness.

此次收购为 PetIQ 不断增长的宠物药品、保健品和健康品牌组合增添了一个领先的、经过临床研究的肌肉健康品牌及其专利 Fortetropin® 成分技术，进一步巩固了其在宠物健康与福祉领域的类别领导地位。

At the core of every MYOS product is Fortetropin®, a proprietary, patented bioactive compound that helps support muscle growth and preservation by modulating myostatin, the body's natural regulator of muscle mass. Fortetropin® has been shown to help build muscle, improve mobility, and reduce the rate of muscle loss associated with aging, injury, or surgery.

MYOS 每款产品的核心成分均为 Fortetropin®，这是一种专有且获得专利的生物活性化合物，通过调节肌肉质量的天然调节因子——肌抑素，来支持肌肉的生长与维持。研究表明，Fortetropin® 有助于增肌、改善活动能力，并减缓因衰老、受伤或手术导致的肌肉流失速度。

Supported by research in both humans and companion animals, including dogs, cats, and horses, Fortetropin® is backed by over a dozen clinical studies, as well as a robust patent portfolio. .

Fortetropin® 得到了包括狗、猫和马在内的伴侣动物以及人类研究的支持，拥有十余项临床研究以及强大的专利组合。

'Pet parents are increasingly looking for solutions that support their pets' mobility, recovery, and long-term vitality — not just treatment after a problem arises,' said Camillo Pane, Chief Executive Officer of PetIQ. 'MYOS has spent over a decade working alongside veterinarians to understand the science around muscle health, leading to the development of Fortetropin® as a proprietary, differentiated, clinically supported ingredient.

PetIQ 首席执行官 Camillo Pane 表示：“宠物主人正日益寻求能够支持宠物行动能力、康复和长期活力的解决方案，而不仅仅是在问题出现后进行治疗。MYOS 与兽医合作十余年，深入探究肌肉健康背后的科学原理，从而开发出 Fortetropin®——一种专有、差异化且具有临床支持的成分。”

Adding MYOS to our leading branded portfolio allows us to enter the fast-growing muscle health category and meet pet owners' growing interest in preventive health, mobility preservation, and quality of life for their pets. We are looking forward to working with the MYOS team and scaling the brand with our insights-first approach, brand building capabilities, and our national retail and e-commerce footprint.' .

将 MYOS 纳入我们领先的自有品牌产品组合，使我们能够进入快速增长的肌肉健康品类，并满足宠物主人对宠物预防保健、行动能力维持和生活质量日益增长的关注。我们期待与 MYOS 团队携手合作，凭借我们以洞察为先的策略、品牌建设能力以及覆盖全国的零售和电子商务网络，共同推动品牌规模化发展。

'We're very excited to partner with PetIQ,' said Joe Mannello, CEO of MYOS Corp. 'PetIQ's distribution reach, brand-building expertise, and operating discipline are exactly what MYOS and Fortetropin® need to realize their full potential and reach more pet owners globally.'

MYOS Corp. 首席执行官乔·曼内洛表示：“我们非常高兴能与 PetIQ 合作。PetIQ 的分销覆盖范围、品牌建设专长以及运营纪律，正是 MYOS 和 Fortetropin® 充分发挥其潜力并触达全球更多宠物主人所需要的。”

MYOS's product lines will become a core offering in PetIQ's broader health & wellness portfolio with the MYOS brand and Fortetropin® ingredient continuing to be marketed under their existing names that pet parents have come to recognize and seek out.

MYOS的产品线将成为PetIQ更广泛的健康与保健产品组合中的核心产品，MYOS品牌和Fortetropin®成分将继续以其现有名称进行市场推广，这些名称已为宠物主人所熟知并主动寻求。

Advisors

顾问

Lincoln International served as financial advisor, and Davis Polk served as legal counsel to PetIQ and Bansk Group. Class VI Partners served as financial advisor, and Davis Graham served as legal counsel to MYOS.

林肯国际担任PetIQ和Bansk集团的财务顾问，戴维斯·波尔克律师事务所担任其法律顾问。Class VI Partners担任MYOS的财务顾问，戴维斯·格雷厄姆律师事务所担任其法律顾问。

About PetIQ

关于 PetIQ

PetIQ is a leading pet health and wellness company delivering pet parents convenient access to over-the-counter ('OTC') pet medications and wellness products. PetIQ is a portfolio company of Bansk Group, a private investment firm that specializes in building distinctive consumer brands.

PetIQ 是一家领先的宠物健康与保健公司，为宠物主人提供便捷的非处方（OTC）宠物药物和保健产品。PetIQ 是 Bansk Group 旗下的投资组合公司，Bansk Group 是一家专注于打造独特消费品牌的私人投资公司。

Headquartered in Idaho, PetIQ's purpose is to champion pet parents in raising healthier, happier pets by delivering smarter pet health and wellness solutions that are innovative, accessible, educational, and always effective. PetIQ specializes in developing, manufacturing, and distributing a diverse portfolio of high-quality, branded health products primarily focused on OTC flea & tick products, dental treats, and other wellness and nutritional products for companion pets.

PetIQ 总部位于爱达荷州，其使命是通过提供创新、易于获取、具有教育意义且始终有效的智能宠物健康与保健解决方案，支持宠物主人养育更健康、更快乐的宠物。PetIQ 专注于开发、制造和分销多样化的高质量品牌健康产品组合，主要聚焦于非处方（OTC）跳蚤和蜱虫防治产品、口腔护理零食，以及伴侣宠物的其他保健和营养产品。

With brands like PetArmor.

包括PetArmor等品牌。

®

®

, Capstar

，Capstar

®

®

, Nextstar

Nextstar

®

®

, Minties

薄荷糖

®

®

, VetIQ

VetIQ

®

注册商标符号

, and Rocco & Roxie

，以及 Rocco & Roxie

®

®

and world-class manufacturing and distribution facilities in Omaha, Nebraska and Springville, Utah, PetIQ is able to deliver trusted solutions to help pets live their best lives, every day.

凭借位于内布拉斯加州奥马哈和犹他州斯普林维尔的世界级制造与分销设施，PetIQ 能够提供值得信赖的解决方案，帮助宠物每天都能享受最佳生活。

About MYOS Corp

关于 MYOS 公司

MYOS Corp is a bio nutrition company focused on the discovery, development, and commercialization of Fortetropin®, a proprietary ingredient supporting muscle health, mobility, and recovery in both human and companion-animal nutrition.

MYOS Corp 是一家生物营养公司，专注于发现、开发和商业化 Fortetropin®，这是一种专有成分，支持人类和伴侣动物营养中的肌肉健康、活动能力和恢复。

About Bansk Group

关于 Bansk 集团

Founded in 2019, Bansk Group is a New York-based private investment firm focused on investing in and building distinctive consumer brands. With over $5 billion in assets under management, the firm partners with differentiated brands across four primary consumer categories: personal care, consumer health, food & beverage, and household products..

Bansk Group 成立于2019年，是一家总部位于纽约的私人投资公司，专注于投资和打造独具特色的消费品牌。该公司管理资产超过50亿美元，与四大主要消费类别中的差异化品牌开展合作，包括个人护理、消费者健康、食品饮料以及家居产品。

Bansk's tenured group of investors and operators have invested more than $30 billion of equity capital across more than 40 transactions with some of the most innovative and well-known consumer companies in the world. With more than three decades of investment experience in the consumer products industry, a global network of relationships, and a tested value creation playbook, Bansk seeks to partner with exceptional founders and management teams to drive outsized organic and acquisitive growth and to position brands for enduring long-term success in the evolving consumer landscape..

Bansk 由资深投资者和运营专家组成的团队，已在全球40多笔交易中投入超过300亿美元的股权资本，投资对象包括全球最具创新力和知名度的消费品公司。凭借在消费品行业逾三十年的投资经验、遍布全球的關係网络以及经过验证的价值创造方法论，Bansk 致力于与杰出的创始人和管理团队合作，推动超常规的有机增长和并购增长，帮助品牌在不断演变的消费市场中确立长期可持续的成功地位。

Media Contact

媒体联系人

Bill Carter

比尔·卡特

EVP & General Counsel

执行副总裁兼总法律顾问

[email protected]

[email protected]

208-869-3665

208-869-3665

SOURCE PetIQ, LLC

来源：PetIQ, LLC

21

二十一

%

百分比

more press release views with

更多新闻稿浏览量与

Request a Demo

申请演示